Susquehanna Maintains Negative on RXO, Lowers Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
Susquehanna analyst Bascome Majors maintains a Negative rating on RXO and lowers the price target from $20 to $16.
September 26, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Susquehanna analyst Bascome Majors maintains a Negative rating on RXO and lowers the price target from $20 to $16, indicating a bearish outlook.
The lowered price target from $20 to $16 by Susquehanna suggests a bearish outlook on RXO, likely leading to negative sentiment and potential short-term price decline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100